Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus

Thrombotic thrombocytopenic purpura (TTP) is a serious disorder with a significant morbidity and mortality. Majority of cases of TTP are idiopathic, but some cases may be secon­dary to connective tissue diseases. TTP has been rarely associated with systemic lupus erythe­matosus (SLE) and may be refractory to treatment with plasma exchange, requiring immuno­suppressive therapy. We describe a patient with TTP and SLE who was refractory to plasma exchange and corticosteroids but responded to anti-CD20 antibody rituximab with continued re­mission after eight months of follow-up. Rituximab appears to be an effective treatment in re­fractory cases of TTP associated with SLE.